IP Library › Granted Patent US 12,648,991
Granted Patent B2
US 12,648,991 · App. 17/783,228 · Granted Jun 9, 2026

Oral respiratory vaccine

Inventors: Rhonda L. LaFleur (Omaha, NE); Jennifer C. Dant (Elkhorn, NE); Ian Tarpey (St. Ives, GB); Zhichang Xu (Omaha, NE)
Assignee: Intervet Inc.
A61K39/155A61K39/099A61P31/04A61P31/14A61K2039/522A61K2039/5254A61K2039/54A61K2039/545A61K2039/552A61K2039/70C12N2760/18734
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,648,991
App. No.
17/783,228
Granted
Jun 9, 2026
Kind
B2
Abstract

The present invention is drawn to new oral live canine parainfluenza virus vaccines and related multivalent vaccines. Methods of using the vaccine alone or in combination with one or more other protective immunogens in multivalent vaccines are also provided.

Claims (10)

1 . An oral bivalent vaccine for providing effective protection to a canine from upper respiratory diseases and infectious tracheobronchitis, the oral bivalent vaccine consisting essentially of a modified live canine parainfluenza (CPI) virus and an avirulent live Bordetella bronchiseptica ( B. bronchiseptica ) and optionally an adjuvant, and wherein the oral bivalent vaccine is formulated for oral administration.

2 . The oral bivalent vaccine of claim 1 , wherein the titer of the avirulent live B. bronchiseptica in the vaccine is about 1×10 7 cfu/mL to about 1×10 12 cfu/mL.

3 . The oral bivalent vaccine of claim 1 , wherein the modified live CPI virus has the ATCC accession No. PTA-126273.

4 . The oral bivalent vaccine of claim 1 , wherein the avirulent live B. bronchiseptica has the ATCC accession No. PTA-126272.

5 . The oral bivalent vaccine of claim 1 , wherein the vaccine is a single-dose oral vaccine.

6 . The oral bivalent vaccine of claim 1 , wherein the vaccine does not comprise an adjuvant.

7 . The oral bivalent vaccine of claim 1 , wherein the vaccine comprises an adjuvant.

8 . The oral bivalent vaccine of claim 1 , wherein the vaccine is formulated for oral administration in a single-dose volume of about 0.2 mL to about 5 mL.

9 . The oral bivalent vaccine of claim 1 , wherein a single dose of the oral vaccine provides effective protection to a canine from upper respiratory diseases and infectious tracheobronchitis for at least 12 months upon administration.

10 . The oral bivalent vaccine of claim 1 , wherein the oral vaccine is lyophilized.

Assignments (5)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2022
From: LAFLEUR, RHONDA L.; DANT, JENNIFER C.; XU, ZHICHANG
To: INTERVET INC.
Reel/Frame 060130/0654 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2022
From: TARPEY, IAN
To: INTERVET UK LTD.
Reel/Frame 060130/0799 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2022
From: INTERVET UK LTD.
To: INTERVET INTERNATIONAL B.V.
Reel/Frame 060130/0933 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2022
From: INTERVET INTERNATIONAL B.V.
To: INTERVET INC.
Reel/Frame 060130/0971 →
Continuity (2)
Provisional Application 62949928 · Dec 18, 2019
Related Publication 20230012140A1 · Jan 12, 2023
References Cited (41)
US 6177082B1 · Dowling et al. · 2001 [cited by applicant]
US 8414901B2 · Callister · 2013 [cited by examiner]
US 8821852B2 · O'Connell · 2014 [cited by examiner]
US 11141545B2 · Anderson et al. · 2021 [cited by applicant]
US 11883476B2 · LaFleur · 2024 [cited by examiner]
US 20180154090A1 · Anderson et al. · 2018 [cited by applicant]
US 20200316192A1 · Tucker et al. · 2020 [cited by applicant]
AU 2019204604A1 · 2019 [cited by examiner]
CN 1835767A · 2006 [cited by applicant]
CN 104411330A · 2015 [cited by applicant]
EP 2129392B1 · 2013 [cited by applicant]
EP 2762163B1 · 2018 [cited by applicant]
EP 3300743A1 · 2018 [cited by applicant]
JP 2008169207A · 2008 [cited by applicant]
RU 2641970C2 · 2018 [cited by applicant]
RU 2696007C1 · 2019 [cited by applicant]
WO WO2004067031A1 · 2004 [cited by applicant]
WO 2008084294A2 · 2008 [cited by applicant]
WO WO2013181086A1 · 2013 [cited by applicant]
WO WO2014029702A1 · 2014 [cited by applicant]
WO 2014147001A1 · 2014 [cited by applicant]
WO WO2020142778A1 · 2020 [cited by examiner]
Hess et al. 2011 (Evaluation of efficacy of oral administration of Bordetella bronchiseptica intranasal vaccine when used to protect puppies from the tracheobronchitis due to B. bronchiseptica infection) (Year: 2011). [cited by examiner]
Hess et al. 2011 (Evaluation of Efficacy of Oral Administration of Bordetella bronchiseptica Intranasal vaccine when used to protect puppies from tracheobronchitis due to B. bronchiseptica infection; Intern J Appl Res V… [cited by examiner]
Kontor et al., 1981, “Canine infectious tracheobronchitis: effects of an intranasal live canine parainfluenza—Bordetella bronchiseptica vaccine on viral shedding and clinical tracheobronchitis (kennel cough),” Am. J. Ve… [cited by applicant]
Shubin, 2017, “canine infectious tracheobronchitis (kennel cough),” Veterinary clinic of Dr. Balakovo Shubin, Dec. 13, 2017. Retrieved from the Internet (Wayback Machine):< URL: https://web.archive.org/web/2017121320172… [cited by applicant]
Chen, Zhenhai et al., A Novel Rabies Vaccine Based on a Recombinant Parainfluenza Virus 5 Expressing Rabies Virus Glycoprotein, Journal of Virology, 2013, 2986-2993, 87:6. [cited by applicant]
Chen, Zhenhai, Parainfluenza virus 5—vectored vaccines against human and animal infectious diseases, Rev Med Virol., 2018, 1-8, 28:e1965. [cited by applicant]
Hess, Thomas J. et al., Evaluation of Efficacy of Oral Administration of Bordetella bronchiseptica Intranasal Vaccine When Used to Protect Puppies from Tracheobronchitis Due to B bronchiseptica Infection, The Journal of… [cited by applicant]
Jacobs, A. A. C. et al., Compatibility of a bivalent modified-live vaccine against Bordetella bronchiseptica and CPiV, and a trivalent modified-live vaccine against CPV, CDV and CAV-2, Veterinary Record, 2007, 41-45, 16… [cited by applicant]
Jacobs, A. A. C. et al., Protection of dogs for 13 months against Bordetella bronchiseptica and canine parainfluenza virus with a modified live vaccine, Veterinary Record, 2005, 19-23, 157. [cited by applicant]
Lehr, Craig et al., Demonstration of 1-Year Duration of Immunity for Attenuated Bordetella bronchiseptica Vaccines in Dogs, Veterinary Therapeutics, 2008, 257-262, 9:4. [cited by applicant]
Merck Animal Health product label for Nobivac Canine 1-DAPPv, downloaded Jun. 1, 2022. [cited by applicant]
Merck Animal Health product label for Nobivac Intra-Trac 3, downloaded Jun. 1, 2022. [cited by applicant]
Merck Animal Health product label for Nobivac Intra-Trac KC downloaded Jun. 1, 2022. [cited by applicant]
United States Department of Agriculture, Center for Veterinary Biologics, Testing Protocol, “SAM 113—Supplemental Assay Method for Titration of Parainfluenza 3 Neutralizing Antibody (Constant Virus—Varying Serum Method)… [cited by applicant]
United States Department of Agriculture, Center for Veterinary Biologics, Testing Protocol, “SAM 309—Supplemental Assay Method for Titration of Canine Parainfluenza Virus in Vero Cell Culture,” No. 309.05, Oct. 30, 2014… [cited by applicant]
United States Patent and Trademark Office, Certified U.S. Appl. No. 62/788,764, filed Jan. 4, 2019 by Merial Inc. (79 pages). [cited by applicant]
United States Department of Agriculture Center for Veterinary Biologics Testing Protocol SAM 309: Supplemental Assay Method for Titration of Canine Parainfluenza Virus in Vero Cell Culture; Oct. 30, 2014, signed Jan. 9 … [cited by third party]
U.S. Appl. No. 62/788,764; filed Jan. 4, 2019; First Named Inventor: Laurent Bernard; 79 Pages. [cited by third party]
United States Department of Agriculture Center for Veterinary Biologics Testing Protocol SAM 113: Supplemental Assay Method for Titration of Parainfluenza 3 Neutralizing Antibody (Constant Virus—Varying Serum Method); D… [cited by third party]